Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| primate origin | 5719 | 2079108-44-2 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Retifanlimab-dlwr binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD-L2, and potentiates T-cell activity. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 22, 2023 | FDA | INCYTE CORP |
None
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anorectal malformation | 56.37 | 52.20 | 6 | 319 | 57 | 110588917 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L01FF10 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| MeSH PA | D000074322 | Antineoplastic Agents, Immunological |
| MeSH PA | D000970 | Antineoplastic Agents |
| FDA MoA | N0000191259 | Programmed Death Receptor-1-directed Antibody Interactions |
| FDA EPC | N0000191260 | Programmed Death Receptor-1 Blocking Antibody |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Merkel cell carcinoma | indication | 253001006 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Programmed cell death protein 1 | Membrane receptor | BINDING AGENT | Kd | 9.22 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| CHEBI:757460 | CHEBI |
| CHEMBL4298037 | ChEMBL_ID |
| C000731936 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11583 | IUPHAR_LIGAND_ID |
| DB15766 | DRUGBANK_ID |
| 4042145 | VANDF |
| 4042146 | VANDF |
| C5401615 | UMLSCUI |
| 11095 | INN_ID |
| 365830 | MMSL |
| 41334 | MMSL |
| d10026 | MMSL |
| 019348 | NDDF |
| D11827 | KEGG_DRUG |
| 2Y3T5IF01Z | UNII |
| 2632980 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ZYNYZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-006 | INJECTION | 25 mg | INTRAVENOUS | BLA | 27 sections |
| ZYNYZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-006 | INJECTION | 25 mg | INTRAVENOUS | BLA | 27 sections |